INTRODUCTION
Streptococcus pneumoniae typically colonizes the respiratory tract asymptomatically but can cause diseases including otitis media, pneumonia, bacteraemia and meningitis. A rare, but devastating complication of pneumococcal invasive disease, is haemolytic uraemic syndrome (HUS). Patients with pneumococcal HUS (pHUS) are typically children and manifest thrombocytopenia, microangiopathic anaemia and renal failure (Cabrera et al., 1998; Cochran et al., 2004; Waters et al., 2007) . Although less common than typical HUS caused by Shiga toxin-expressing Escherichia coli, pHUS has higher morbidity and mortality (McGraw et al., 1989; Cabrera et al., 1998; Nathanson & Deschênes, 2001) . Patients are more likely to require dialysis, have longer hospital stays and suffer long-term health consequences compared to typical HUS patients (McGraw et al., 1989; Cabrera et al., 1998; Nathanson & Deschênes, 2001 ; Brandt et al., 2002; Constantinescu et al., 2004) . Although pHUS is rare, studies suggest an increase in the proportion of invasive pneumococcal disease associated with HUS since the introduction of the seven-valent conjugate vaccine (Waters et al., 2007; Copelovitch & Kaplan, 2008 , 2010 Bender et al., 2010; Hsiao et al., 2015) . Furthermore, in some countries, S. pneumoniae is the most common cause of HUS (Cabrera et al., 1998; Cochran et al., 2004; Constantinescu et al., 2004; Waters et al., 2007; Chen et al., 2011; Lee et al., 2012) . Despite the severity of pHUS, the pathogenesis is poorly defined, and clinicians cannot predict which patients will develop this complication. There are significant correlations between the development of pHUS and specific pneumococcal serotypes, empyema and necrotizing pneumonia (Cabrera et al., 1998; Brandt et al., 2002; Waters et al., 2007; Bender et al., 2010; Banerjee et al., 2011; Lee et al., 2012; Janapatla et al., 2013) .
The pathophysiology of pHUS is poorly understood but is proposed to involve both host and bacterial factors. Genetic variants of complement genes that associate with complement-mediated atypical HUS are present in some pHUS patients (Szil agyi et al., 2013) . It has long been proposed that pneumococcal neuraminidase contributes to pHUS development (Klein et al., 1977) . Neuraminidases cleave terminal sialic acid from host surfaces and expose the Thomsen-Friedenreich antigen (T-antigen, galactose b, 1,3-N-acetylgalactosamine) (Klein et al., 1977; McGraw et al., 1989; Coats et al., 2011) (Fig. 1 ). All individuals develop antibodies to the T-antigen, as this structure is present on the surface of pathogenic bacteria (Poulsen, 1961; Bray et al., 1981; Crookston et al., 2000) . The binding of anti-T IgM to the exposed T-antigen is proposed to be responsible for the subsequent pathological effects, although the role of antibody in disease pathogenesis is controversial (Kim et al., 1979; Springer & Tegtmeyer, 1981; McGraw et al., 1989; Eber et al., 1993; Crookston et al., 2000) . Alternatively, desialylation of host surfaces may reduce factor H binding leading to unchecked complement activation and increased injury to host cells (Ault, 2000) . Supporting that hypothesis, recent studies suggest that complement dysregulation and consumption occur during pHUS (Gilbert et al., 2013; Szil agyi et al., 2013) .
Pneumococcal strains encode up to three neuraminidases (C amara et al., 1994; Berry et al., 1996; Tettelin & Hollingshead, 2004; Xu et al., 2011) . Previous studies have demonstrated the gene encoding NanA is present in all strains tested; NanB is encoded by approximately 96 % of strains; and NanC, by up to 51 % of strains (King et al., 2005; Pettigrew et al., 2006; Imai et al., 2011) . nanA is required for T-antigen exposure in mice, but it is not clear which neuraminidase(s) is required for T-antigen exposure in humans (Coats et al., 2011) . A study from Taiwan found that the presence of nanC correlated with pHUS, but similar studies have not been conducted in other geographical regions (Janapatla et al., 2013) . Neuraminidase activity distinguishes pHUS from other causes of HUS; however, the precise role of neuraminidase-mediated T-antigen exposure in pHUS remains unclear (Szil agyi et al., 2015) . Most patients with pHUS are T-antigen positive; however, so are many other invasive pneumococcal disease patients (Huang et al., 2006) . While it has been suggested that neuraminidase levels may be higher in pHUS isolates (Geary, 2007; Copelovitch & Kaplan, 2008) , other studies do not support this hypothesis (Coats et al., 2011; Smith et al., 2013) .
Pneumococcal O-glycosidase Eng (endo-a-N-acetylgalactosaminidase) is specific for the T-antigen and so will also contribute to the levels of this carbohydrate exposed on host surfaces (Bhavanandan et al., 1976; Caines et al., 2008; Giefing et al., 2008; Marion et al., 2009; King, 2010) (Fig. 1) . The distribution of eng remains to be defined. One study suggested that the gene was present in all sequenced strains, while another reported that 8 % of strains lack the gene (Marion et al., 2009; Giefing et al., 2010) . However, both studies identified diversity within the gene that could affect enzyme activity. Furthermore, although studies of Oglycosidase activity have been limited, significant differences were observed between strains (Marion et al., 2009) . Thus, differences in eng distribution, alleles or Eng expression could contribute to the development of pHUS.
This study uses a cohort of 29 pHUS isolates from the USA between 1998 and 2011 and matched controls to further our understanding of the roles of pneumococcal glycosidases in pHUS. In summary, we found no significant correlation between the distribution of genes encoding neuraminidases or O-glycosidase or the resulting enzymatic activities and pHUS. Furthermore, we identified no differences in distribution of genomic elements that likely explain which patients develop pHUS. the incidence and epidemiological characteristics of invasive disease caused by S. pneumoniae. To protect patient privacy, only the year of infection and age of the patient were provided (Table 1) .
Bacterial growth and DNA preparation. S. pneumoniae was grown at 37 C in 5 % CO 2 on tryptic soy (Becton, Dickinson and Co.) plates with 1.5 % agar that was spread with 5000 U of catalase (Worthington Biochemical Corporation) or supplemented with 5 % sheep blood. Broth cultures were routinely grown at 37 C in Todd-Hewitt broth supplemented with 0.2 % (w/v) yeast extract (Becton, Dickinson and Co.) . DNA was prepared as previously described by Whatmore et al. (1999) , with the exception of that used for genomic sequencing of strains which was prepared using the Gentra Puregene Yeast/Bacterial Kit (Qiagen). To better mimic growth in blood, bacteria for glycosidase activity assays were grown in C-medium with 5 % yeast extract (pH 6.8) containing 6 mM glucose as a carbon source (Lacks & Hotchkiss, 1960) .
Multilocus sequence typing, distribution of glycosidases and diversity of Eng. To determine the genetic background of isolates, we performed multilocus sequence typing (MLST) as previously described by Enright & Spratt (1998) . Alleles and sequence types (STs) were assigned using data available on the MLST website (http://www.mlst. net/). The relationship of the assigned STs to others present in the MLST database was assessed using the database available in eBURST at the time of submission (http://eburst.mlst.net/) (Feil et al., 2004) . New STs were assigned to existing eBURST groups containing single-locus variants of these STs.
The presence of genes encoding the three pneumococcal neuraminidases (nanA, nanB and nanC) and the O-glycosidase (eng) was assessed by PCR using the forward (F) and reverse (R) primers and standard PCR conditions (Table 2 ). To determine if there were any statistically significant correlations between distribution of glycosidases and disease state (pHUS isolates and blood non-pHUS isolates), twotailed chi-squared tests were performed. Three strains gave smaller than expected products for nanB; these were sequenced using Sanger sequencing (accession no. KX134672-74). The eng gene and upstream region of 12 selected strains was amplified as two overlapping PCR products using primer pairs eng S1 and S2 and eng S3 and S4 and sequenced with additional primers (Table 2) (accession no. KX102615-26).
The absence of nanC from PCR-negative strains was confirmed by Southern blotting using EcoRV-digested DNA and standard protocols. Membranes were probed with a DIG-labelled 519 bp internal fragment of nanC (primers nanCF and nanCP, PCR DIG Probe Synthesis; Roche Diagnostics). Hybridization was performed at 65 C, and washes were performed at 68 C decreasing from 2 to 0.2Â SSC. Bound probe was detected using the DIG nucleic acid detection kit (Roche Diagnostics).
Enzymatic assays. Aliquots of cultures were taken at ODs at 600 nm of 0.2, 0.4 and 0.6. Extracellular glycosidase activity assays were performed essentially as previously described except that they were scaled for a 96-well plate format (King et al., 2004; Marion et al., 2009) . Absorbance of a medium-only control was subtracted from all data points. All experiments were performed three times in triplicate, and the data were plotted as the mean of each independent experiment±SD. Two-way ANOVA with repeated-measures factor was used to determine the correlation between enzymatic activities and disease state.
Expression of glycosidases in blood. Pneumococci grown to an OD at 600 nm of 0.4±0.005 were washed twice in PBS, resuspended in blood at an equivalent of an OD at 600 nm of 0.6 and incubated at 37 C for 30 min. Thirty minutes was chosen to maximize chances of observing any alterations in gene expression while minimizing the risks of differences in growth rate affecting outcomes. RNA isolated using an acid-phenol extraction, with modifications for S. pneumoniae, was treated with DNase I (New England Biolabs) and subsequently purified using a Qiagen RNeasy minikit (Johnston, 2009; Linke et al., 2013) . cDNA was generated with SmartScribe reverse transcriptase according to the manufacturer's instructions (Clontech). Negative controls were processed without the addition of reverse transcriptase. The brilliant SYBR green QRT-PCR Master Mix (Stratagene) was used according to the manufacturer's instructions. Reactions were performed on an Mx3005 multiplex quantitative PCR system (Stratagene) using the SYBR green protocol. Cycling parameters were as follows: 95 C for 10 min and then 40 cycles of 95 C (30 s), 60 C (1 min) and 72 C (30 s), followed by melting curve analysis. Names of primers used for detection of transcripts contain the letter Q (Table 2 ). All reactions were performed in triplicate on three independent biological replicates with reference dye normalization. For each sample, a gene expression normalization factor was calculated using the geometric mean of two housekeeping control genes (rpoB and gyrB) (Vandesompele et al., 2002) . This factor was used to generate a normalized expression value for the gene of interest, and statistical analysis was performed. Mann-Whitney U test was applied to determine the correlation between level of transcripts of these genes and disease state.
Genomic sequencing. Genomic sequencing was conducted by the Biomedical Genomics Core at the Nationwide Children's Hospital using standard protocols. In brief, 2.5 µg of high-quality genomic DNA was sheared to approximately 350 bp size fragments using Covaris S2. DNA libraries were generated with TruSeq PCR-Free Sample Preparation kit (Illumina) and purified using AMPure XP System (Beckman Coulter). After confirmation of library quality, paired-end 100 bp sequence reads were generated using the Illumina HiSeq2500 platform. De novo assembly of the genome sequence was performed to avoid bias that can occur when reads are mapped to known sequences (accession nos LXPJ00000000-LXPN00000000 and LXJK00000000). Genomic analysis was performed by ERA7. In brief, the genome sequences were assembled with SPAdes and annotated using BG7 (Bankevich et al., 2012; ParejaTobes et al., 2012) . The final assemblies were aligned to the reference genome TIGR4 using Harvest, which was also used to identify single nucleotide polymorphisms (SNPs) (Treangen et al., 2014) . Alignments generated using Mauve (Darling et al., 2004) were used to identify substitutions, insertions and deletions of each pHUS isolate as compared to TIGR4 using the Differences program (developed by Era7 Bioinformatics). After identification of genetic elements found in the majority of pHUS isolates and not TIGR4, the distribution of these elements in available genomes was determined. The distribution of the second insertion was determined by PCR using primers Ins2F and Ins2R (Table 2 ) and any correlation with disease state assessed by the twotailed chi-squared test.
RESULTS

Genetic background of pHUS isolates
Most pHUS isolates collected between 1998 and 2011 were obtained from children 2 years or younger (82.8 %). Two additional isolates were from children between 3 and 5 years of age. Although pHUS is typically a childhood disease, there were also two isolates from adults. The 29 isolates represented 10 serotypes, the most common of which was 19A (48.3 %). In addition, one isolate was non-typeable. Our control group consisted of 31 non-HUS invasive disease isolates matched for isolate serotype and patient age. To determine if there were any differences in the genetic background of pHUS and control isolates, we performed MLST (Enright & Spratt, 1998) . The 60 isolates represented 29 STs, six of which were novel (Table 1 ). The most common ST was (Feil et al., 2004) .
Distribution of neuraminidases in pHUS isolates and controls
As all three pneumococcal neuraminidases can cleave a-2,3-linked sialic acid that commonly decorates the T-antigen, they could all potentially contribute to pHUS (C amara et al., 1994; Gut et al., 2008; Xu et al., 2008 Xu et al., , 2011 . To assess differential distribution, we screened our strains for the presence of the genes encoding the three neuraminidases by PCR. As expected, all isolates contained nanA. The presence of nanB was determined using primers within the flanking genes. Consistent with published data, 95 % of the isolate contained nanB (57/60) ( Table 1 ) (Pettigrew et al., 2006) . However, the remaining three strains gave a much smaller amplified product than expected (~450 bp). Sequencing of these products revealed the absence of nanB and the presence of a pneumococcal BOX element (Fig. 2) . BOX elements are interspersed composite repeats consisting of boxA and boxC sequences typically separated by a variable number of boxB elements (Martin et al., 1992) . In this case, in the place of nanB was a reverse complement of a BOX ABC element. Although we cannot definitively determine the direction of the horizontal gene transfer event, given that most strains contain nanB and the GC content of nanB is similar to the surrounding genes, we predict that the BOX element replaced nanB. One recombination site appears to be located within the stop codon of the gene upstream of nanB, SP_1686. The stop codon is maintained but altered from TAG to TAA. This TAA forms the start of the reverse complement of the C repeat. In addition to the BOX element, all three strains possess 29 bp downstream of the BOX element that shares 18 nucleotides with the final 27 bp of the nanB gene. It is highly likely that the second recombination event occurred between the 3¢ region of nanB and a region distal to the BOX element within the donor. Neither the predicted ribosome binding site nor the coding sequence of the gene downstream of nanB was altered. These three strains are not closely related, as they are of distinct eBURST groups. There was no difference in distribution of nanB between pHUS and control isolates (93.1 % vs 96.8 %; P=0.9527).
PCR screening and Southern blotting indicated that 17 of the 60 strains (28.3 %) were positive for nanC (Table 1 and data not shown). There was no difference in distribution of nanC between pHUS and control isolates (27.6 % vs 30.0 %; P=0.8378). Together, these data suggest that, at least in the USA, there is no correlation between neuraminidase distribution and pHUS.
Pneumococcal HUS isolates do not possess higher neuraminidase activity
Previous studies have not addressed whether neuraminidase activity is altered in pHUS isolates prior to the late exponential phase of growth. As neuraminidase activity increases as cultures reach late exponential phase, it is possible that regulation of neuraminidases in pHUS is altered (King et al., 2004; Trappetti et al., 2009) . Thus, we selected six pHUS and six non-HUS controls representing a range of different genetic backgrounds as defined by eBURST groups and measured activity at the early, mid and late exponential growth phases. Although there was variation in neuraminidase activity between strains, there was no association between disease state and neuraminidase activity (F=0.03867; P=0.8480) (Fig. 3) . 
Pneumococcal HUS isolates do not possess lower O-glycosidase activity
No prior studies have addressed the role for S. pneumoniae O-glycosidase Eng in pHUS. It was previously suggested that the gene is absent in some pneumococcal strains; however, we detected eng in all 60 isolates (Giefing et al., 2008) . To explore diversity within eng, the gene and promoter sequence were obtained from the same six pHUS and six non-HUS controls used to measure neuraminidase activity. Sequence alterations were observed at 4.6 % (82/1767 amino acids) of residues in the protein, although none of these were in the residues predicted to be essential from the protein structure (Caines et al., 2008; Willis et al., 2009) . Eight different alleles were identified, but the sequence diversity between them was low with a maximum divergence of 2.3 %. Despite the variation in predicted Eng sequence, there were no particular differences associated with pHUS. The intergenic region upstream of eng contained a conserved sigma 70 core promoter TTGCTTN 14 TGTTATATT (Solovyev & Saloamov, 2011) . The minimum sequence identity between intergenic regions was 96.7 %. Fig. 3 . Levels of O-glycosidase (a) and neuraminidase (b) activity. Six pHUS strain and six blood non-HUS controls were used to assess any differences in enzyme activity between strains. Strains were grown to ODs at 600 nm of 0.2, 0.4 and 0.6. Aliquots of total culture were incubated with the substrate 2¢-(4-methyl-umbelliferyl)-a-D-N-acetylneuraminic acid (a) or . After termination of the reactions, activity was measured as appropriate, and a no-bacterial control was subtracted from each data point. Values are the mean of three independent experiments±SD. Two-way ANOVA with repeated-measures factor was used to determine the association between enzymatic activities and disease state. No significant correlation was observed between O-glycosidase (F=0.08942; P=0.7710) or neuraminidase (F=0.03867; P=0.8480) activity and disease state.
As sequence diversity could contribute to differences in Oglycosidase activity, we measured activity of the same 12 strains at the early, mid and late exponential phases. Although there were differences in activity between strains, there was no significant correlation between disease state and O-glycosidase activity (F=0.08942; P=0.7710) (Fig. 3) .
While growth in glucose-containing media can mimic aspects of bacterial growth in blood, there are also key differences. As it is impossible to measure real-time growth of our pneumococcal strains in blood and to accurately measure glycosidase activity using fluorescent or colorimetric assays, we used quantitative PCR to examine transcript levels of nanA, nanB and eng after 30 min incubation in blood. Although transcript levels varied between strains, there was no significant correlation between the transcript levels and disease state (data not shown, nanA: P=0.167, nanB: P>0.999, eng: P=0.373 ).
Sequence of pHUS isolates
Previously published comparative genomic hybridization of four ST199 pHUS isolates with non-HUS isolates showed few differences in genomic content (Smith et al., 2013) . However, genetic elements required for pHUS may have been missed, as this analysis was limited to the genes found in TIGR4 and R6. We sequenced and de novo assembled genome sequences of six pHUS strains representing six different STs (Table 1) . Each of these genome sequences was compared to TIGR4, and a large number of SNPs were identified. A total of 1160 were common to all six pHUS isolates, while there were between 971 and 10 927 specific to each comparison (Fig. S1 , available in the online Supplementary Material). The comparison revealed that, as expected, the strains varied in similarity to TIGR4 with ABC010016366 being the most distant genetically (Figs S2 and S3) . In addition to changes in the capsule locus, two large insertions were identified in pHUS isolates. At least part of each insertion was identified in each pHUS genome with the exception of ABC010016366. The first locus included genes predicted to encode components of a phosphotransferase system transporter, a glycosidase, sulfatase and ROK family regulator. Sequence analysis suggests that the predicted proteins may contribute to utilization of a sulfated glycosaminoglycan (Altschul et al., 1990; Cantarel et al., 2009) . However, as this locus was present in 81.5 % of sequenced genomes, it seems unlikely to confer the ability to cause pHUS and thus was not further considered. The second locus encodes predicted components of an ATPbinding cassette transporter, glycosidase, carbohydrate modification enzymes and a regulator. Sequence analysis suggests that predicted proteins may contribute to utilization of a poly-mannose-containing glycan (Altschul et al., 1990; Cantarel et al., 2009) . This locus was present in 27 % of pneumococcal genome sequences; hence, we determined the distribution in the pHUS and non-HUS strains used in this study. As 68 % of pHUS isolates and 65 % of non-HUS isolates contain this locus, there is no correlation between presence of this locus and disease state (P=0.761).
DISCUSSION
It has long been suggested that T-antigen exposure on the surface of blood, epithelial and endothelial cells by pneumococcal neuraminidase leads to pHUS (Klein et al., 1977) . Still, it is puzzling why only a small percentage of people with invasive pneumococcal disease develop pHUS. One possible explanation is that individual pneumococcal strains have different abilities to expose the T-antigen. Enhanced T-antigen exposure could occur by increased neuraminidase activity or decreased O-glycosidase activity. In contrast to a previously published study, we observed no correlation between nanC and pHUS (Janapatla et al., 2013) . While it is possible that the strains from different geographical regions have distinct mechanisms of pHUS pathogenesis, these data may suggest a local epidemiological link between nanC and strains that cause pHUS in Taiwan. An in vitro study of nine pHUS isolates showed no significant correlation between neuraminidase activity during late exponential growth and disease state (Smith et al., 2013) . We extended these studies to demonstrate that there were no significant correlations between activity at the early and mid-exponential phases of in vitro growth and pHUS.
This is the first study to address a potential role for pneumococcal O-glycosidase in pHUS. In contrast to a previously published study, we observed that all strains tested contain eng and that the level of sequence diversity was relatively low (Giefing et al., 2008) . Furthermore, there was no significant correlation between activity and disease state. Although we cannot rule out that pHUS isolates express increased neuraminidase activity or decreased O-glycosidase activity in vivo, our studies examining transcript levels of glycosidases in blood provide no evidence to support that hypothesis. Furthermore, genomic sequencing of pHUS isolates did not identify any genomic elements likely to contribute to pHUS.
Although exposure of the T-antigen likely contributes to pHUS pathogenesis, our data support the suggestion that host genetics factors, host immunity or environmental factors influence which patients develop pHUS during invasive pneumococcal disease (Smith et al., 2013) .
